Recombinant Human Insulin in Global Diabetes Management – Focus on Clinical Efficacy
Open Access
- 1 January 2017
- journal article
- review article
- Published by Touch Medical Media, Ltd. in touchREVIEWS in Endocrinology
- Vol. 13 (1), 21-25
- https://doi.org/10.17925/EE.2017.13.01.21
Abstract
Biosynthetic human insulin and insulin analogues are the mainstay of insulin therapy for both type 1 and type 2 diabetes although access to human insulin at affordable prices remains a global issue. The world is experiencing an exponential rise in the prevalence of diabetes presenting an urgent need to establish effective diabetes therapy in countries burdened by inadequate health care budgets, malnutrition and infectious diseases. Recombinant human insulin has replaced animal insulins and animal-based semisynthetic human insulin thereby available in sufficient quantities and at affordable prices able to provide global access to insulin therapy. In many patients, analog insulins can offer additional clinical benefit, although at a considerably higher price thus severely restricting availability in low income countries. The approval process for recombinant human insulins (i.e. biosimilars) and analogue insulins is highly variable in the developing countries in contrast to Europe and in North America, where it is well established within a strict regulatory framework. This review aims to discuss the future access to human insulin therapy in a global context with an ever increasing burden of diabetes and significant economic implications.Keywords
This publication has 28 references indexed in Scilit:
- Insulin therapy in pregnancy.2016
- A Real-World Study of the Effect of Timing of Insulin Initiation on Outcomes in Older Medicare Beneficiaries with Type 2 Diabetes MellitusJournal of the American Geriatrics Society, 2015
- The Alarming and Rising Costs of Diabetes and Prediabetes: A Call for Action!Diabetes Care, 2014
- Pediatric diabetes: Potential for insulin degludecIndian Journal of Endocrinology and Metabolism, 2014
- Patient Perspectives on Biosimilar InsulinJournal of Diabetes Science and Technology, 2014
- Economic Costs of Diabetes in the U.S. in 2012Diabetes Care, 2013
- Standards of Medical Care in Diabetes—2012Diabetes Care, 2011
- Global healthcare expenditure on diabetes for 2010 and 2030Diabetes Research and Clinical Practice, 2010
- Is Glycemic Control Improving in U.S. Adults?Diabetes Care, 2008
- A New Semisynthesis of Human InsulinHoppe-Seyler´s Zeitschrift für physiologische Chemie, 1976